FDA clears ELGEMS artifact correction

August 19, 1998

The Food and Drug Administration has cleared a nonuniform attenuation correction package developed by nuclear medicine firm ELGEMS of Tirat Hacarmel, Israel. The upgrade, called VTransACT, works on dual-head variable-angle gamma cameras manufactured by

The Food and Drug Administration has cleared a nonuniform attenuation correction package developed by nuclear medicine firm ELGEMS of Tirat Hacarmel, Israel. The upgrade, called VTransACT, works on dual-head variable-angle gamma cameras manufactured by ELGEMS, which are sold by Elscint as VariCam and by GE Medical Systems as Millennium VG. Elscint plans to begin shipments of VTransACT for VariCam in the first quarter of 1999, according to a spokesperson for the company. ELGEMS also received 510(k) clearance for a set of ultra-high-energy collimators, called VPC-94. The collimators are designed to be used on VariCam for FDG cardiac imaging.